Ruling Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation
Paragon becomes the first patent holder to survive a post grant review challenge
PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) – Paragon BioTeck, Inc., (Paragon) announces a monumental ruling handed down by the United States Patent and Trademark Office affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
